|
Dr. Sandra Silberman recently joined Tapestry as chief medical officer. Dr. Silberman began her career in clinical development at Pfizer, Inc., where she initiated the Company’s first program in clinical oncology and oversaw the introduction of Tarceva into clinical trials. She then served as Senior Director for Novartis Clinical Research, where she led the global development of Gleevec, a highly innovative drug and the first targeted therapy for chronic myelogenous leukemia. Dr. Silberman subsequently joined Eisai Medical Research as Global Therapeutic Area Head (Oncology), a role in which she advanced six novel compounds into Phases I through III in clinical development. As an independent industry consultant over the years, Dr. Silberman has advised Bristol-Myers Squibb, AstraZeneca, Imclone, Roche, and GPC-Biotech in their various oncology programs.
Dr. Silberman earned her Ph.D. in Tumor Immunology from Johns Hopkins University and her M.D. from Cornell University Medical College. She completed a fellowship in hematology/oncology at the Brigham & Women’s and the Dana Farber Cancer Institute in Boston. She has numerous publications and is named on several patents in the cancer drug development field, including novel anti-tubulin agents for advanced solid tumors. She is board certified in Internal Medicine and Hematology. | 